Exploring Novel Treatment Developments in Radiation Oncology
Adaptive radiation may help individualize therapy based on transient factors patients are faced with while receiving treatment for cancer.
Optimizing Opportunities to Deliver Personalized Radiation Oncology Care
Experts from Sibley Memorial Hospital highlight radiation oncology technologies that have played key roles in cancer care at their institution.
Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC
The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.
Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment
Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.
Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies
“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.
Multidisciplinary Care is ‘Incredibly Important’ for Managing GI Cancers
“[There] is a need to make sure that everybody is coming in and bringing their expertise together,” Valerie Lee, MD, said.
FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer
Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.
ASTCT Women’s History Month Spotlight: Terri Lynn Shigle, PharmD
For Terri Lynn Shigle, PharmD, the field of hematology-oncology is deeply personal. Having lost loved ones to cancer, she was drawn to a career where she could make a meaningful difference in patient care.
ASTCT Women’s History Month Spotlight: Sung-Yun Pai, MD
In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy.
Prioritizing Climate Hazard Preparedness Following NSCLC Surgery
Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.
Omitting Breast Surgery Stalls Cancer Recurrence in Exceptional Responders
At 5 years, 100% of patients with breast cancer who did not receive surgery had ipsilateral breast tumor relapse-free survival.
FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC
Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.
Tisotumab Vedotin Earns Japanese Approval in Advanced Cervical Cancer
Tisotumab vedotin elicited a median OS of 11.5 months vs 9.5 months with chemotherapy in advanced cervical cancer in the phase 3 innovaTV 301 trial.
Sharing Knowledge is Key for Climate Disaster Preparedness in Cancer Care
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
Chemotherapy Results in Greater Pain/Fatigue Vs Endocrine Therapy in Breast Cancer
Patients with breast cancer who were treated with chemotherapy may have more pain, fatigue, and difficulty moving vs those who received endocrine therapy or did not have breast cancer.
The Intricacies of Sequencing Immunotherapy in GI Cancers
Valerie Lee, MD, said that deciding where to implement immunotherapy into cancer treatment often depends on the type of disease.
2025 ACRO Summit Shows ‘Amazing Prospects’ in Radiation Oncology
A radiation oncologist discussed challenges related to the radiation oncology space as well as ongoing developments in the field highlighted at ACRO.
Tobacco Control Helps Avert Millions of Lung Cancer Deaths
A stronger commitment to tobacco control at the local, state, and federal levels may further improve progress in preventing smoking-related mortality.
CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC
CAN-2409 plus valacyclovir or acyclovir elicited a median OS of 24.5 months in the overall population of patients who progressed after immune checkpoint inhibitor therapy.
Olvi-Vec Exhibits Preliminary Efficacy in Advanced Small Cell Lung Cancer
Intravenous olvi-vec demonstrated a manageable safety and tolerability profile consistent with previous trials evaluating the investigational agent.
ACRO SEAL Helps Build Programs for New Radiation Oncology Practitioners
A radiation oncologist discussed the theranostics treatment landscape and career opportunities in the field at the 2025 ACRO Summit.
Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer
The blood test showed consistent, strong results in high-risk subgroups such as those with familial history, pancreatic cysts, or diabetes.
Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months
A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.
Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer
The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.
Hospital Length of Stay After NSCLC Surgery Higher With Wildfire Exposure
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors
Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.
Discussing the Applicability of ACRO Findings to Radiation Oncology Practice
ACRO presentations may enable community practices to utilize cutting-edge radiation advances to deliver optimal treatment to patients.
Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC
In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.
